Wednesday, March 23, 2011

KaloBios Pharmaceuticals starts test of potential leukemia drug

KaloBios Pharmaceuticals Inc. started an early stage test of a treatment aimed at leukemia.
The South San Francisco business treated the first patient in a Phase I trial of KB004, a monoclonal antibody the company has developed. The drug targets the protein EphA3, which is significant in several types of cancer.

No comments:

Post a Comment